ImmunityBio, Inc. (IBRX) vs Kymera Therapeutics, Inc. (KYMR)
ImmunityBio, Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. ImmunityBio, Inc. and Kymera Therapeutics, Inc. are of similar size ($9.7B and $9.2B). ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 134.8%. Kymera Therapeutics, Inc. has the higher net margin (−285.3% vs −598.6%) and the lower return on invested capital (−26.7% vs 0.00%). Across the 17 metrics below, ImmunityBio, Inc. leads on 11 and Kymera Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | IBRX | KYMR | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.34% | 100.00% | 65.16% |
| Operating margin | (151.88%) | (333.50%) | 0.00% |
| Net margin | (598.56%) | (285.33%) | 0.00% |
| Free cash flow margin | (173.76%) | (226.62%) | 0.00% |
| Return on equity | 122.85% | (24.15%) | (57.72%) |
| Return on assets | (192.58%) | (21.58%) | (49.22%) |
| Return on invested capital | 0.00% | (26.72%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack